Tests a PET-CT scan for diagnosing endometriosis before surgery
Tests a FAPI PET-CT scan in adults with suspected endometriosis before surgery.
Plain-language title generated from the registry record
Registry title: The Role of FAPI PET-CT in Diagnosing Endometriosis
Key facts
- Where
- Safed, IsraelSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 45 years old?
Source: NCT06792318, who can take part
Where in Israel
- Ziv Medical CenterSafed, IsraelTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ziv Hospital
- Trial code
- NCT06792318
- Record updated
- 24 January 2025
- Original description
Patients with suspected endometriosis scheduled for surgery will be identified. They will be asked to participate in a study evaluating the feasibility of FAPI PET-CT in diagnosing endometriosis. The results will be compared with surgical findings, pathology, and other imaging techniques if available (i.e., MRI, US).Read full original descriptionShow less
Use of Fibroblast Activation Protein Inhibitor (FAPI) PET-CT Before Surgery in Patient with Endometriosis
Patients with suspected endometriosis scheduled for surgery will be identified. They will be asked to participate in a study evaluating the feasibility of FAPI PET-CT in diagnosing endometriosis. The results will be compared with surgical findings, pathology, and other imaging techniques if available (i.e., MRI, US).
Inclusion: Female participants aged 18-45 years; Clinical suspicion of endometriosis based on symptoms; Scheduled for diagnostic/therapeutic laparoscopic surgery; Ability to understand and provide written informed consent; Completed and signed Radiation Exposure Documentation Form.
Exclusion: Exposure to ionizing radiation for medical purposes within 12 months prior to enrollment; History of pelvic radiation therapy; Known active malignancy; Pregnant women or women who are breastfeeding.